drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody (biologic)
drug_description
Chimeric IgG1 anti-EGFR monoclonal antibody that blocks EGFR signaling and mediates ADCC.
nci_thesaurus_concept_id
C1723
nci_thesaurus_preferred_term
Cetuximab
nci_thesaurus_definition
A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.
drug_mesh_term
Cetuximab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric IgG1 monoclonal antibody targeting EGFR; binds the receptor’s extracellular domain to block ligand binding, activation, and dimerization, thereby inhibiting downstream RAS/MAPK and PI3K/AKT signaling and tumor cell proliferation. Its Fc region also engages Fcγ receptors to mediate antibody-dependent cellular cytotoxicity (ADCC) against EGFR-expressing cells.
drug_name
Cetuximab
nct_id_drug_ref
NCT06107114